Exenatide vs SLU-PP-332
Side-by-side comparison of Exenatide and SLU-PP-332: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Exenatide
SLU-PP-332
Exenatide
Exenatide (Byetta, Bydureon) is a synthetic exendin-4 GLP-1 receptor agonist, FDA-approved for type 2 diabetes, that lowers blood glucose and curbs appetite. Available as a twice-daily immediate-release and a once-weekly…
No vendor price on file.
Full Exenatide profileSLU-PP-332
SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023…
Lowest listed price: $69.99 across 5 listings
Full SLU-PP-332 profileSide-by-side comparison
| Attribute | Exenatide | SLU-PP-332 |
|---|---|---|
| Category | Weight Loss | Performance |
| Research Stage | FDA-approved | Preclinical |
| Mechanism of Action | Exenatide is a synthetic form of exendin-4, a 39-amino-acid peptide first isolated from the saliva of the Gila monster (Heloderma suspectum). It shares about 53 percent of its sequence with human GLP-1 but, unlike native GLP-1, resists breakdown by the DPP-4… | SLU-PP-332 acts through pan-agonism of the three estrogen-related receptors (ERRα/NR3B1, ERRβ/NR3B2, ERRγ/NR3B3), a subfamily of orphan nuclear receptors that regulate oxidative metabolism, mitochondrial biogenesis, and exercise-responsive gene expression. The… |
| Half-Life | Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks. | — |
| Typical Dose Range | 5 to 10 mcg twice daily (Byetta, immediate-release) or 2000 mcg (2 mg) once weekly (Bydureon, extended-release) | Research compound — no established human doses. Animal studies: 10-50 mg/kg |
| Dosing Frequency | Twice daily before meals (immediate-release) or once weekly (extended-release) | — |
| Administration | — | — |
| Side Effects | Gastrointestinal effects are by far the most common: nausea (reported in roughly 40 to 57 percent of patients on the twice-daily form, usually worst early and fading over weeks), vomiting, diarrhea, constipation, and dyspepsia. Reduced appetite is expected.… | The side effect profile of SLU-PP-332 in humans is undocumented because no clinical trials have been conducted. Rodent studies report generally acceptable tolerability at doses producing exercise-mimetic metabolic effects, without overt signs of toxicity on… |
| Molecular Weight | 4186.6 g/mol (molecular formula C184H282N50O60S) | 535.54 g/mol |
| Common Vial Sizes | — | — |
Price History
3 data points- Half Nattys
- Ion Peptide
- BHG Labs
Exenatide: potential benefits
- Meaningful glycemic control in type 2 diabetes, with HbA1c reductions of roughly 1.0 to 1.9 percent in randomized trials
- Weight reduction of about 2 to 3 kg in diabetic trials, driven mainly by reduced appetite and slower gastric emptying
- Low intrinsic hypoglycemia risk because insulin release is glucose-dependent (risk rises when combined with sulfonylureas or insulin)
- Strong control of post-meal glucose spikes
- Cardiovascular safety shown in a large outcomes trial, with no increase in major cardiac events
- Can be added to basal insulin to improve control while offsetting insulin-related weight gain
- Once-weekly extended-release option (Bydureon) reduces injection burden versus twice-daily dosing
- In people without diabetes the appetite effect is real, but standalone weight loss has been modest and less consistent than newer agents such as [semaglutide](/compound/semaglutide) or [tirzepatide](/compound/tirzepatide)
SLU-PP-332: potential benefits
- Exercise mimicry without physical exertion
- Enhanced fat oxidation
- Increased mitochondrial biogenesis
- Improved endurance capacity
- Muscle fiber type conversion
- Metabolic health improvement
Frequently asked
What's the difference between Exenatide and SLU-PP-332?
Exenatide is a weight loss that exenatide is a synthetic form of exendin-4, a 39-amino-acid peptide first isolated from the saliva of the gila monster (heloderma suspectum). it shares about 53 percent of its…. SLU-PP-332 is a performance that slu-pp-332 acts through pan-agonism of the three estrogen-related receptors (errα/nr3b1, errβ/nr3b2, errγ/nr3b3), a subfamily of orphan nuclear receptors that regulate oxidative…. The two differ in mechanism, half-life (Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks. vs not reported), and typical dose range.
Which has the longer half-life, Exenatide or SLU-PP-332?
Exenatide has a half-life of Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks.. SLU-PP-332 has a half-life of not reported. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack Exenatide and SLU-PP-332?
Stacking depends on mechanism overlap, safety profile, and goals. Exenatide and SLU-PP-332 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Exenatide or SLU-PP-332
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.